France Tightens Health Spending For 1997

13 January 1997

The ceiling on French medical spending in 1997, including drug spendingand medical treatment, has been fixed at 262.2 billion French francs ($50.53 billion) compared with 258.8 billion francs in 1996, a rise of only 1.3%. After fixing public-sector hospital spending growth limits, Social Affairs Minister Jacques Barrot has imposed a tight regime of austerity on the doctors.

The budget ceiling becomes official this week (January 14) in an agreement on health service "objectives and management" between the health fund organization, the CNAM, and the government.

One doctors' organization, the CSMF, has already described the spending growth limit as a form of health care rationing which does not take account of needs. However, Mr Barrot has already made some concessions in relation to the budget limits in response to hostility from the medical profession. Antiretroviral drugs, for example, are excluded from part of the budget calculation, as are some drugs purchased in pharmacies but which have been prescribed at consultations "external to the hospital."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight